Adagene Inc.
ADAGHealthcare|Biotechnology|CN
$2.00
-0.02 (-0.99%)
Tangible Book / Share
$2.34
Cash / Share
$2.82
Clinical Trials (14)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04524871 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Advanced Liver Cancers | P1P2 | Active | 518 | RCT, Open-label | Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg |
| NCT05405595 ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors | P1P2 | Recruiting | 186 | RCT, Open-label | ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib) |
| NCT05275777 A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | HER2-negative Breast Cancer, Advanced Solid Tumor | P1P2 | Active | 66 | Open-label | ADG106, Doxorubicin, Cyclophosphamide, Paclitaxel |
| NCT06846268 Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | Locally Advanced Colorectal Cancer | P2 | Recruiting | 20 | Open-label | ADG126, Pembrolizumab |
| NCT05491083 Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | Advanced Solid Tumor, Triple Negative Breast Cancer | P1P2 | Recruiting | 51 | Open-label | Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) |
| NCT05614258 Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors | P1 | Active | 14 | Open-label | ADG206 |
| NCT04775680 Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | Solid Tumor, Non Hodgkin Lymphoma | P1P2 | Terminated | 25 | Open-label | ADG106 injection, PD-1 antibody injection |
| NCT04645069 ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors | P1P2 | Completed | 58 | Open-label | ADG126 Mono, ADG126-anti PD1, ADG126-ADG106 |
| NCT05236608 A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC | Metastatic Non Small Cell Lung Cancer | P1P2 | Unknown | 53 | Open-label | Nivolumab, ADG106 |
| NCT04501276 A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients | Advanced/Metastatic Solid Tumors | P1 | Completed | 72 | Open-label | ADG116, ADG106, anti PD1 drug |
| NCT03707093 Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | Solid Tumors, Non-Hodgkin Lymphoma | P1 | Completed | 49 | Open-label | ADG106 |
| NCT05277402 ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors | P1 | Completed | 6 | Open-label | ADG116 |
| NCT04111445 Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors | Solid Tumor | P1 | Terminated | 1 | Open-label | ADG116 |
| NCT03802955 Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | Solid Tumor, Non-Hodgkin Lymphoma | P1 | Completed | 62 | Open-label | ADG106 |